Hydrix Limited Overview
Hydrix Limited is an Australian micro-cap technology company whose core asset is Hydrix Services, a Melbourne-based multidisciplinary engineering consultancy that designs and develops safety-critical products — principally Class III active implantable cardiovascular devices, surgical robotics and, increasingly, sovereign defence systems — for international medtech start-ups and Australian defence primes. Around three-quarters of FY2026 revenue came from outside Australia. Around this fee-for-service engine the group has layered three option-value businesses: Hydrix Medical (distribution of the Implicity AI remote cardiac monitoring platform in Australia and Southeast Asia), Hydrix Ventures (equity stakes in former clients such as Gyder Surgical and Wavewise), and, since May 2026, Hydrix Defence, a vehicle to acquire, licence or develop proprietary defence intellectual property. The company has never been profitable at group level, carries negative shareholders' equity, depends on director-provided debt and equity, and in 2026 recapitalised at A$0.005 per share. It is best characterised as a distressed-but-recapitalised engineering services platform pivoting toward technology ownership.
Company's own description (paraphrased from the FY2026 Appendix 4E Operational and Financial Review). Hydrix states its purpose as enhancing people's health, safety and well-being by leveraging its product innovation capability across four business segments operated through four wholly owned subsidiaries. During FY2026 its principal activities were product design and development consulting for clients in the medical and defence technology sectors, marketing remote cardiac monitoring technology, and managing a portfolio of venture investments in early-stage medtech companies. The listed parent, Hydrix Limited, is not itself a revenue-generating unit. The FY2026 Chairman's Letter recasts the group as an Australian technology company spanning medical technology, defence, industrial and mining, combining engineering, technology investment, IP development and commercialisation.
The four segments (FY2026 definitions):
-
Hydrix Services — end-to-end multidisciplinary product design and development consulting across medtech, cardiac health, defence and industrial sectors: safety-critical control systems engineering, software, electronics, mechanical, human factors and industrial design; services span applied research, engineering design, prototyping, manufacturer management and certification process management. This segment produced substantially all group revenue in FY2024–FY2026.
-
Hydrix Defence (established May 2026) — evaluating investments, acquisitions and IP licensing to own technologies delivering higher-value, longer-duration revenue; areas of interest include embedded intelligence, autonomy-enabling technologies, advanced sensing, electronic warfare, navigation and counter-UAS, aligned to Australian Defence Force (ADF) capability needs, border security and critical infrastructure protection.
-
Hydrix Medical — distributes Implicity's cloud-based, AI-driven remote cardiac patient monitoring and data management platform under licence across Australia and Southeast Asia (sales focus: Australia, Singapore, New Zealand). Previously also distributed the Avertix Medical (formerly Angel Medical Systems) Guardian implantable heart-attack warning system, whose distribution-rights asset was impaired to nil in FY2024.
-
Hydrix Ventures — selectively invests in Hydrix Services medtech clients to generate equity capital gains; current portfolio: Gyder Surgical Pty Ltd (orthopaedic hip-replacement navigation tool) and Wavewise Pty Ltd (non-invasive brain trauma injury monitoring device).
Business and revenue model. Revenue is overwhelmingly professional services (fee-for-service, time-and-materials and milestone-based engineering contracts) recognised as "revenue from contracts with customers". There is a small product element: Hydrix has sold units of its proprietary LUDO mechanical heart controller (five units sold in FY2024) to clients developing total artificial heart and assistive heart technologies, which the company positions as a lead-generator for subsequent fee-for-service work. Hydrix Medical targets software-as-a-service recurring revenue (pipeline cited at >A$2.5m ARR in FY2024, >A$2.0m in H1 FY2025 and >A$1.5m in H1 FY2026), but had not reported material recognised revenue from it in the periods reviewed. Hydrix Ventures generates no operating revenue; its results flow through fair-value gains and losses on financial assets. No licensing royalties are disclosed.
Value-chain position. Hydrix sits in the outsourced product development (OPD) / engineering-services layer between a client's concept and contract manufacturing. It does not manufacture at scale, but offers "manufacturer management" and regulatory/certification support. In medtech it acts as design-and-development partner for start-ups that lack in-house engineering depth, particularly for high-risk implantables; in defence it acts as an engineering subcontractor to primes and SMEs (e.g., NIOA Group, Phasor Innovation).
Customer types and end-markets.
Independent characterisation. Hydrix is, in substance, a ~50-person specialist engineering consultancy with a niche reputation in Class III cardiovascular implantables, bolted to a listed shell with ~A$116 million of accumulated losses (the bulk inherited from the Panorama Synergy era and the post-2017 investment phase). Its revenue base (~A$10 million) has been flat-to-declining for three years, its client base is concentrated in venture-funded start-ups whose funding volatility directly hits Hydrix's utilisation (as the SynCardia pause in Q4 FY2026 showed), and its balance sheet has relied on director loans and letters of comfort. The 2026 strategic pivot toward defence IP ownership is coherent with Australian sovereign-capability spending trends but is, as yet, unfunded beyond the 2026 entitlement offer and unproven.
Strategy
Stated strategy (themes from FY2026 Chairman's Letter and Appendix 4E, paraphrased).
-
From services to technology ownership. Leverage the high-value engineering services capability to pursue technology and IP ownership in high-priority Australian sovereign capability domains, aiming for larger, recurring revenue streams; the stated objective is to combine world-class engineering services with valuable proprietary technology and IP.
-
International medtech growth. Pursue larger international medtech programs (core growth strategy), particularly cardiovascular and safety-critical devices and surgical robotics.
-
Sovereign defence growth. Use Hydrix Services' decade-plus of defence program experience and the new Hydrix Defence subsidiary to address ADF capability needs (sensing, autonomy, EW, navigation, counter-UAS), border security and critical infrastructure.
-
Disciplined Medical commercialisation. Progress Implicity commercialisation while matching investment to customer and reimbursement milestones.
-
Capital preservation in Ventures. Continue supporting portfolio companies but deploy no new venture capital (none deployed in FY2026).
-
Simplified capital structure. Use the 2026 equity raise and debt conversion to reduce cash obligations and enable growth.
Strategic initiatives register (last 24 months).
ESG/sustainability commitments: none disclosed. Medium-term financial targets: none disclosed. The only forward-looking quantitative markers are pipeline figures: estimated future program value in excess of A$37m across more than 15 active client programs (FY2026), down from ~A$40m cited repeatedly through FY2024–H1 FY2026; ~A$4.0m of contract sales signed since 30 June 2026 (to 28 Aug 2026); and A$6.5m of new contracts referenced in the June 2026 quarterly as supporting the FY2027 revenue outlook.
Products & Services
Hydrix Services — capabilities
| Offering | Description / capability | Target customer | Pricing model | Source |
|---|---|---|---|---|
| Safety-critical control systems engineering | Design of control systems where failure risks life, incl. Class III active implantables | Cardiovascular medtech developers | Fee-for-service, milestone | Appendix 4E FY2026; FY2024 report |
| Embedded software engineering | Safety-critical software, firmware (e.g., Remedy Robotics N1) | Medtech robotics, defence | Fee-for-service | Chairman's Letter FY2026 |
| Electronics engineering | Embedded electronics, sensing | Medtech, defence | Fee-for-service | Chairman's Letter FY2026 |
| Mechanical engineering & industrial design | Product mechanical design, enclosures, mechanisms | All sectors | Fee-for-service | Appendix 4E FY2026 |
| Human factors & UX engineering | Usability engineering for regulated devices | Medtech | Fee-for-service | Morningstar profile; Appendix 4E |
| Regulatory, clinical, reimbursement & quality systems consulting | Certification process management, regulatory submissions support | Medtech start-ups | Fee-for-service | Morningstar profile; Appendix 4E |
| Applied research → prototyping → manufacturer management | Full lifecycle from research to transfer-to-manufacture | All | Fee-for-service | Appendix 4E FY2026 |
| Systems engineering for defence | Counter-UAS payload subsystems, quantum navigation support | Defence primes/SMEs | Contract | Chairman's Letter FY2026 |
Proprietary products
| Product | Description | Launch / status | Pricing | Source |
|---|---|---|---|---|
| LUDO mechanical heart controller | Hydrix-developed and owned controller technology used by clients developing total replacement and assistive heart devices | 5 units sold in FY2024 | — | Appendix 4E FY2024 |
Named client programs / products developed by Hydrix Services (illustrative portfolio)
| Client / product | Description | Year referenced | Source |
|---|---|---|---|
| SynCardia Systems (USA) — Emperor Total Artificial Heart | A$2.5m development contract for next-generation TAH; paused Q4 FY2026 pending client funding | FY2026 | 4C Jan 2026; Appendix 4E FY2026 |
| Remedy Robotics (USA) — N1 remote endovascular intervention robot | A$3.4m contract for safety-critical software and embedded electronics | FY2026 | Chairman's Letter FY2026 |
| Quantanosis — robotic stroke therapy platform | Next-generation robotic stroke therapy development support | FY2026 | Chairman's Letter FY2026 |
| NIOA Group (Australia) — counter-UAS payload subsystem | A$1.2m defence development contract | FY2026 | Chairman's Letter FY2026 |
| Phasor Innovation — quantum sensing & navigation | Navigation for GPS-denied undersea, maritime, airborne and land applications | Jun 2026 | ASX 4 Jun 2026; Chairman's Letter |
| Gyder Surgical — GYDER Hip System | Orthopaedic hip-replacement navigation tool; FDA 510(k) Feb 2025; US commercialisation began 2026 | 2025–2026 | 4C Apr 2025; Appendix 4E FY2026 |
| Wavewise — non-invasive brain monitor | Continuous monitor to detect brain hypoxia / trauma | FY2023–FY2026 | Appendix 4E FY2024, FY2026 |
| Unnamed USA client — remotely operated catheter-guidance robot | Endovascular interventions | FY2024 | Appendix 4E FY2024 |
| Unnamed European client — Left Ventricular Assist Device | Cardiac | FY2024 | Appendix 4E FY2024 |
| Unnamed European client — Total Artificial Heart | Cardiac | FY2024 | Appendix 4E FY2024 |
| Unnamed European client — wound therapy device | Medtech | FY2024 | Appendix 4E FY2024 |
| Memphasys — Felix System | Sperm-separation device; positive results reported | FY2023 | Appendix 4D Feb 2023 |
| Chemring — portable EM blocking device | Defence/security sensing | Historical | Morningstar profile |
| Universal Biosensors — coagulation analyser | Diagnostics | Historical | Morningstar profile |
| Micro-X — mobile X-ray | Imaging | Historical | Morningstar profile |
| Angel Medical Systems / Avertix — Guardian | Implantable heart-attack warning system (Hydrix also built devices) | 2020 onward | Biotech Daily 2020 |
The five largest FY2024 clients (the unnamed USA, Europe and Australia programs above) delivered A$7.25m of FY2024 revenue (~68% of revenue, derived) — Appendix 4E FY2024.
Hydrix Medical
| Product | Description | Territory | Status | Pricing | Source |
|---|---|---|---|---|---|
| Implicity remote cardiac monitoring platform | Cloud-based, AI-driven remote monitoring and data management for cardiac implantable device patients | Australia, Southeast Asia (sales focus Australia, Singapore, NZ) | Licensed May 2023; pipeline >A$1.5m ARR (H1 FY2026); long, reimbursement-dependent sales cycles | SaaS (rates not disclosed) | Appendix 4E FY2024, FY2026; Appendix 4D Feb 2026 |
| Avertix Medical Guardian | Implanted real-time heart-attack warning system | Singapore, Malaysia, Thailand approvals; Australia (TGA application withdrawn 2023) | 8 sales/implants in Singapore to FY2024; distribution rights impaired to nil at 30 Jun 2024 | — | Appendix 4E FY2024 |
| Second AI cardiovascular product (FY2023 agreement) | One of two AI cardiovascular distribution agreements announced FY2023 (other than Implicity) | — | Not named in sources reviewed; no subsequent disclosure | — | FY2023 results announcement |
Hydrix Ventures
| Investee | Description | Status | Source |
|---|---|---|---|
| Gyder Surgical Pty Ltd | GYDER Hip System; FDA 510(k) Feb 2025; US commercialisation commenced 2026; recent capital raise at lower valuation → A$2.3m mark-down | Held | Appendix 4E FY2026 |
| Wavewise Pty Ltd | Non-invasive brain trauma monitoring | Held | Appendix 4E FY2026 |
| Avertix Medical (formerly Angel Medical Systems) | Guardian owner; Nasdaq IPO filing 2023; written down to A$0.14m Aug 2024 | No longer listed among portfolio companies in FY2026 (portfolio now "two" companies, versus three in FY2025) | Appendix 4E FY2024, FY2025, FY2026 |
Hydrix Defence
| Focus area | Description | Status | Source |
|---|---|---|---|
| Embedded intelligence & autonomy | Technologies for field-ready sovereign assets in contested environments | Evaluating acquisitions/licences | Appendix 4E FY2026 |
| Advanced sensing, electronic warfare, navigation, counter-UAS | Aligned to ADF priorities | Pipeline; no acquisition announced as of the dossier date | Chairman's Letter FY2026 |
| European defence market engagement | Business development activity | Announced 17 Jun 2026 | ASX announcement |
Financial Narrative
Income statement
Sources and notes: FY2025–FY2026 line items from the FY2026 Appendix 4E consolidated statement of profit or loss (unaudited FY2026). FY2022–FY2024 revenue and net loss from aggregator series (Stoxray/TipRanks) cross-checked against company statements: FY2024 revenue A$10.6m and loss A$9.6m (Appendix 4E FY2024 — includes A$4.2m non-cash/non-recurring items incl. A$2.5m Guardian impairment and A$1.75m Avertix write-down); FY2023 revenue is reported by the company as A$13.3m (FY2023 results announcement) versus A$13.16m on aggregators — the difference likely reflects inclusion of other income; FY2023's unusually small net loss (A$0.40m) is per aggregator data and was not reconciled to the audited FY2023 statements in this research. FY2021 net loss was A$9.78m (Appendix 4E FY2021). EPS FY2023/FY2024 per Simply Wall St (7 Oct 2024); FY2025/FY2026 per Appendix 4E FY2026 (the 4E column layout was cross-checked against weighted share counts). Derived EBITDA = loss before tax + finance costs + D&A − interest income. Gross profit is not reported (Hydrix presents expenses by nature, not cost of sales).
Margins and growth
Revenue CAGR FY2022–FY2026 (derived): −1.4% per annum (A$10.33m → A$9.74m). FY2022 growth derived from aggregator FY2021 revenue of A$7.45m.
Commentary. The five-year picture is one of a services business that briefly scaled (FY2023 peak of ~A$13.2–13.3m, driven by 34% fee-revenue growth and 34% international growth) and then contracted as venture-funded clients delayed or cancelled programs in the tighter post-2022 funding environment. FY2024 revenue fell 19% on client funding challenges, budget constraints, delayed commencements and program completions (Appendix 4E FY2024). Management responded with cost reductions (A$1.7m annualised in FY2024; A$3.2m savings cited in FY2025), which drove the improvement in the FY2025 loss before tax from A$9.6m to a statutory A$3.65m (the FY2025 results summary cited A$2.9m on an adjusted basis). FY2026 regressed: revenue slipped a further 3.5% due to client-funding-driven delivery slippage, chiefly the Q4 pause in SynCardia's Emperor program; the statutory loss nearly doubled to A$6.72m, but A$2.75m of this was non-cash fair-value loss (A$2.3m attributable to the Gyder mark-down). The adjusted loss widened modestly to A$3.96m from A$3.19m. The structural problem is visible in the cost base: employee costs absorb ~89% of revenue, leaving no room for overhead, finance costs (A$1.2m, ~12.5% of revenue, reflecting 8–12% related-party loans), or D&A. Breakeven requires either ~A$13–14m of revenue at current cost or materially higher utilisation and pricing.
Balance sheet
Sources: Appendix 4E FY2026 balance sheet and statement of changes in equity (FY2024 closing equity, issued capital and accumulated losses taken from the 1 July 2024 opening balances); FY2024 cash from the FY2025 cash flow statement opening balance; Ventures values FY2023–FY2024 from Appendix 4E FY2024 (the FY2023 results announcement separately cited Ventures NTA of A$4.9m — a discrepancy with the A$5.1m figure quoted in FY2024, likely reflecting different measurement dates or bases).
Commentary. Hydrix has had negative equity since at least FY2024, deepening to −A$8.15m at 30 June 2026 despite the A$5.3m equity raise (net of costs, including A$3.45m allocated to option reserves) because of the A$6.72m loss and the collapse of the Ventures portfolio value. Borrowings (A$7.25m, all current at 30 June 2026) consist mainly of loans and convertible notes owed to directors (A$5.9m) plus A$0.2m external convertible notes. After balance date, up to A$5.1m of debt-conversion commitments were secured; the company states that if no further shortfall capital is raised, A$3.9m will convert, leaving pro forma residual debt of A$2.2m (excluding accrued interest). Pro forma, this would improve equity by A$3.9m but equity would remain negative (derived: roughly −A$4.3m) absent further raises. The A$1.0m trade debtors facility at Hydrix Services was extinguished from the raise proceeds.
Cash flow
Sources: Appendix 4E FY2026 cash flow statement (FY2025, FY2026); Appendix 4E FY2024 (FY2024 OCF A$1.9m used and FY2023 A$2.7m used; FY2024 receipts A$12.3m). FY2022 OCF from aggregator series (Stoxray). Note: Stoxray reports FY2023 OCF as −A$3.12m versus the company's −A$2.7m; the company figure is used and the discrepancy flagged.
FY2026 quarterly cash profile (AUD millions)
Sources: Appendix 4C reports (28 Oct 2025; 30 Jan 2026, amended 2 Feb 2026; 30 Jul 2026). Q3 operating cash flow is derived as the full-year figure less the other three quarters. Q1 and Q3 revenue were not captured from primary sources.
Commentary. Operating cash burn had narrowed impressively from ~A$6.6m (FY2022) to ~A$0.5m (FY2025), demonstrating the cost-out program's effectiveness, before re-widening to A$1.9m in FY2026, almost entirely in Q4 (A$1.63m outflow), when SynCardia work stopped and a receivable was delayed while staff costs (A$2.39m in the quarter) continued. The business is extremely sensitive to single-client timing. Capex is negligible (~A$50k a year), consistent with an asset-light consultancy. Funding has come entirely from directors' loans, letters of comfort (A$2.0m in Aug 2024, A$2.5m in total by Oct 2025, A$2.2m cited Feb 2026) and, in FY2026, the entitlement offer.
Ratios
Notes: ROE and debt/equity are not meaningful because equity is negative; ROIC and net debt/EBITDA are not meaningful because EBIT and EBITDA are negative (cells left blank). Cash conversion cycle: not publicly disclosed (receivables of A$1.50m against revenue of A$9.74m imply roughly 56 days of sales outstanding at FY2026 year end, derived, but payables-days data is incomplete). Revenue per employee FY2025 matches the TipRanks figure of A$183.5k.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segments Reported by Period
| Period | Segments reported | Change |
|---|---|---|
FY2019–FY2023 | Hydrix Services; Hydrix Medical; Hydrix Ventures (Ventures from 2019; Medical from 2020) | Medical added after Guardian rights acquisition (2020) |
FY2024–FY2025 | Services; Medical; Ventures (some aggregators describe "two segments", Services and Medical, treating Ventures as investment holdings) | Guardian impaired to nil; Implicity becomes main Medical product |
FY2026 | Services; Defence; Medical; Ventures | Hydrix Defence added May 2026 (minimal costs in FY2026) |
Revenue by Segment
| Segment | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Hydrix Services revenue (AUD Mn) | 10.61 | 10.09 | 9.74 |
Hydrix Medical revenue (AUD Mn) | 0 | 0 | 0 |
Hydrix Ventures operating revenue (AUD Mn) | 0 | 0 | 0 |
Hydrix Defence revenue (AUD Mn) | — | — | 0 |
Group revenue from contracts with customers (AUD Mn) | 10.61 | 10.09 | 9.74 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansRevenue by Segment and Segment Margins & Growth (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Services % of group revenue | 100 | 100 | 100 |
Services revenue YoY growth (%) | -19 | -4.9 | -3.5 |
Services signed contract value (AUD Mn) | — | 9.9 | 11.7 |
Segment profit metric (AUD Mn)
| Segment profit metric (AUD Mn) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Hydrix Services cash operating profit, H1 only (AUD Mn) | — | 0.42 | — |
Hydrix Ventures fair-value movement (AUD Mn) | -1.75 | 0.15 | -2.75 |
Hydrix Ventures portfolio book/NTA value at year end (AUD Mn) | 3.35 | 3.17 | 0.42 |
Hydrix Limited (parent) operating cost increase (AUD Mn) | — | — | 0.1 |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from contracts with customers (AUD Mn) | 10.33 | 13.16 | 10.61 | 10.09 | 9.74 |
Other income incl. interest (AUD Mn) | — | — | — | 0.18 | 0.11 |
Total income (AUD Mn) | — | — | — | 10.27 | 9.86 |
Employee benefits expense (AUD Mn) | — | — | — | 8.93 | 8.65 |
Project material expenses (AUD Mn) | — | — | — | 0.56 | 0.86 |
Other expenses (AUD Mn) | — | — | — | 1.76 | 2.00 |
Depreciation & amortisation (AUD Mn) | — | — | — | 0.76 | 0.53 |
Finance costs (AUD Mn) | — | — | — | 1.05 | 1.22 |
Fair-value loss on financial instruments (AUD Mn) | — | — | — | 0.46 | 2.75 |
Total expenses (AUD Mn) | — | — | — | 13.93 | 16.57 |
Loss before income tax (AUD Mn) | — | — | — | -3.65 | -6.72 |
Net loss after tax (AUD Mn) | -5.55 | -0.40 | -9.56 | -3.65 | -6.72 |
Adjusted loss excl. non-cash FV losses (AUD Mn) | — | — | — | -3.19 | -3.96 |
EBITDA, derived (AUD Mn) | — | — | — | -1.86 | -5.00 |
EBITDA excl. FV losses, derived (AUD Mn) | — | — | — | -1.39 | -2.25 |
Basic & diluted EPS (AUD cents) | — | -0.2 | -3.8 | -1.38 | -1.86 |
Dividends per share (AUD cents) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue growth YoY (%) | 38.7 | 27.4 | -19.2 | -4.9 | -3.5 |
Revenue less project materials margin, derived proxy (%) | — | — | — | 94.4 | 91.2 |
Operating (EBIT) margin, derived (%) | — | — | — | -26.0 | -56.8 |
EBITDA margin, derived (%) | — | — | — | -18.4 | -51.3 |
EBITDA margin excl. FV losses, derived (%) | — | — | — | -13.8 | -23.1 |
Net margin (%) | -53.7 | -3.0 | -90.1 | -36.2 | -69.0 |
Employee costs as % of revenue (%) | — | — | — | 88.4 | 88.8 |
Balance Sheet and Per-Share Data
| Metric | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Total assets (AUD Mn) | — | — | 7.62 | 6.09 |
Cash & cash equivalents (AUD Mn) | — | 0.91 | 0.30 | 2.96 |
Trade & other receivables (AUD Mn) | — | — | 1.73 | 1.50 |
Financial assets at FVTPL — Ventures (AUD Mn) | 5.1 | 3.35 | 3.17 | 0.42 |
Intangible assets (AUD Mn) | — | — | 0.18 | 0 |
Goodwill (AUD Mn) | — | — | 0 | 0 |
Right-of-use assets (AUD Mn) | — | — | 0.96 | 0.59 |
Current borrowings (AUD Mn) | — | — | 6.08 | 7.25 |
Non-current borrowings (AUD Mn) | — | — | 1.00 | 0 |
Total borrowings (AUD Mn) | — | — | 7.08 | 7.25 |
Lease liabilities, total (AUD Mn) | — | — | 1.58 | 1.09 |
Net debt excl. leases, derived (AUD Mn) | — | — | 6.79 | 4.29 |
Net debt incl. leases, derived (AUD Mn) | — | — | 8.36 | 5.39 |
Total liabilities (AUD Mn) | — | — | 14.39 | 14.24 |
Total equity (AUD Mn) | — | -3.36 | -6.77 | -8.15 |
Issued capital (AUD Mn) | — | 102.13 | 102.41 | 104.28 |
Accumulated losses (AUD Mn) | — | -105.84 | -109.24 | -115.88 |
Working capital, derived (AUD Mn) | — | — | -9.27 | -8.57 |
NTA per share (AUD cents) | — | — | -2.55 | -0.56 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Receipts from customers incl. GST (AUD Mn) | — | — | 12.3 | 10.08 | 11.02 |
Net operating cash flow (AUD Mn) | -6.58 | -2.7 | -1.89 | -0.53 | -1.91 |
Capex: PP&E + intangibles (AUD Mn) | — | — | — | 0.05 | 0.05 |
Free cash flow, derived (AUD Mn) | — | — | — | -0.58 | -1.96 |
Proceeds from share issues (AUD Mn) | — | — | — | 0 | 5.22 |
Net borrowings (AUD Mn) | — | — | — | 1.05 | 0.52 |
Interest and finance costs paid (AUD Mn) | — | — | — | 0.44 | 0.60 |
Lease repayments (AUD Mn) | — | — | — | 0.68 | 0.48 |
Dividends paid (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Cash Flow (Quarterly)
| Metric | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Q4 FY2026 |
|---|---|---|---|---|
Quarterly revenue (AUD Mn) | — | 2.3 | — | 2.2 |
Net operating cash flow (AUD Mn) | -0.28 | 0.05 | -0.05 | -1.63 |
Cash at quarter end (AUD Mn) | 0.31 | 0.58 | — | 2.96 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2025 | FY2026 |
|---|---|---|
Return on assets, year-end assets, derived (%) | -48.0 | -110.4 |
Current ratio, derived (x) | 0.22 | 0.36 |
Interest coverage, EBIT/finance costs (x) | -2.5 | -4.5 |
Asset turnover, year-end assets, derived (x) | 1.32 | 1.60 |
Revenue per employee, derived (AUD K) | 183 | 195 |
Revenue by Region (%) and Revenue by Region
| Metric | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
International share of revenue (%) | 57 | 73 | 63 | 73 |
Australian share of revenue (%) | 43 | 27 | 37 | 27 |
International revenue, derived (AUD Mn) | 7.50 | 7.75 | 6.36 | 7.11 |
Australian revenue, derived (AUD Mn) | 5.66 | 2.86 | 3.73 | 2.63 |
International revenue growth, derived (%) | — | 3.3 | -17.9 | 11.8 |
Australian revenue growth, derived (%) | — | -49.5 | 30.4 | -29.5 |
Share Price History
| Date | Price (AUD) | Context | Source |
|---|---|---|---|
7 Nov 2018 | 0.037 | Name change to Hydrix | InvestSMART |
Apr 2022 | ~0.10 | Placement | MarketIndex |
Sep 2022 | ~0.06 | Rights issue | MarketIndex |
Dec 2024 | ~0.012 | Director remuneration shares | MarketIndex |
28 Oct 2025 | 0.015 | Q1 FY2026 4C | InvestSMART |
30 Jan 2026 | 0.017 | Q2 FY2026 4C | InvestSMART |
27 Feb 2026 | 0.016 | Half-year update | InvestSMART |
18 May 2026 | 0.013 | Entitlement offer announced (offer price 0.005) | InvestSMART |
19 Aug 2026 | 0.003 | Post-raise | InvestSMART |
Aug–Oct 2026 | 0.003–0.004 | Latest observed | InvestSMART; StockLight |
Valuation Multiple Details
| Valuation multiple | Value | Comment |
|---|---|---|
Market capitalisation | ~A$4–5m (aggregators) | May understate post-conversion share count |
EV/Sales (derived, FY2026) | ~0.9x–1.0x | EV ≈ ~A$5m market cap + A$7.25m debt − A$2.96m cash ≈ ~A$9.3m pre-conversion; post-conversion EV broadly similar as debt converts to equity |
P/S | ~0.4x–0.5x | TipRanks shows 0.43x (2025) |
Analyst Conclusions
Management guidance. No numerical revenue or earnings guidance. Management states FY2027 should become a period of meaningful value creation as engineering services growth combines with Defence and medical technology commercialisation; it cites A$11.7m FY2026 contract sales, ~A$4.0m of sales since year end, more than 15 active programs with estimated future value above A$37m, new client projects replacing SynCardia from the September 2026 quarter, and SynCardia's possible restart once funded. Consensus: none available.
Bull case
-
Order intake leads revenue. FY2026 signed contract value rose 18% to A$11.7m with ~A$4.0m added in July–August 2026; if delivered on schedule, FY2027 revenue could exceed the FY2024–FY2026 range of A$9.7–10.6m, and at ~89% employee-cost intensity, incremental utilisation flows strongly to EBITDA.
-
Balance-sheet reset. Conversion of A$3.9–5.1m of 8–12% director debt removes most of the ~A$1.2m annual finance cost and the current-liability overhang, with A$2.96m cash at 30 June 2026 providing runway that Hydrix lacked in 2025.
-
Defence optionality at a tiny valuation. With A$2.9m of defence contract sales already and exposure to counter-UAS and quantum navigation, a single successful IP acquisition or licence in a high-priority sovereign domain could re-rate a company valued at roughly 1x EV/sales.
Bear case
-
Structural unprofitability. The adjusted loss widened to A$3.96m in FY2026 despite two years of cost-cutting; revenue has declined three years running, and the business has never shown sustained group profitability.
-
Fragile client base. One client's funding pause (SynCardia) produced a A$1.63m Q4 cash outflow; with most clients venture-funded start-ups, similar shocks are likely to recur.
-
Dilution and capital dependence. The 6-for-1 issue at A$0.005, conversions and ~1 billion-plus options create heavy overhang; the defence acquisition strategy will probably require further equity at depressed prices, and negative equity persists even after conversion.
Key catalysts and monitorables (next 12 months)
Concluding analyst verdict.
Hydrix Limited is best understood as two businesses sharing one fragile balance sheet. The first is a genuinely capable, if small, safety-critical engineering consultancy whose credentials in total artificial hearts, LVADs and surgical robotics have won it repeat international work: 73% of FY2026 revenue came from overseas, and contract signings rose 18% to A$11.7m. The second is a listed shell carrying A$116 million of accumulated losses, negative equity of A$8.2 million and a history of option-value ventures — the Guardian distribution rights, the Avertix stake, and now the Gyder mark-down — that have destroyed rather than created value. FY2026 crystallised both: management secured marquee contracts and recapitalised the company, yet revenue fell for a third successive year, the adjusted loss widened, and a single client's funding pause produced the worst quarterly cash burn in two years.
The 2026 recapitalisation materially improves near-term survival odds. Converting most of the directors' 8–12% loans into equity at A$0.005 and holding A$2.96 million of cash at year end gives Hydrix more room than at any point since FY2023. However, the cost is extreme dilution, a large option overhang to 2029, and a capital structure in which further raises are likely if the defence acquisition strategy is pursued in earnest.
The investment case therefore rests on execution evidence that does not yet exist: quarterly revenue recovering above A$2.5–3.0 million as new programs replace SynCardia, operating cash flow returning to breakeven, and a first credible Hydrix Defence IP transaction that does not require ruinous dilution. Until those markers appear, Hydrix should be treated as a highly speculative, binary micro-cap — a call option on Australian sovereign-defence demand and cardiovascular engineering niche demand, underwritten largely by its own directors. Monitoring the October 2026 audited accounts and the next two quarterly cash flow reports is essential before forming any higher-conviction view.
Principal sources
-
Hydrix Limited, Appendix 4E Preliminary Final Report, year ended 30 June 2026 (unaudited), 28 Aug 2026
-
Hydrix Limited, Executive Chairman's Letter, 28 Aug 2026
-
Hydrix Limited, Appendix 4E Preliminary Final Report FY2025, 29 Aug 2025; FY2024 Preliminary Final Report & Market Update, 30 Aug 2024; FY2023 results announcement, 29 Aug 2023; Appendix 4E FY2021 and FY2019
-
Hydrix Limited, Appendix 4D half-year reports (Feb 2023, Feb 2024, Feb 2025, Feb 2026)
-
Hydrix Limited, Appendix 4C quarterly reports (Jan 2025, Apr 2025, Jul 2025, Oct 2025, Jan/Feb 2026, Jul 2026)
-
Hydrix Limited, Prospectus — Entitlement Offer (18 May 2026) and related announcements (20 May, 25 May, 10 Jun, 16 Jun, 18 Jun 2026)
-
Hydrix Limited, Annual Report FY2025 (Grant Thornton auditor; Company Secretary details)
-
Biotech Daily (17 Jul 2020; 15 Feb 2023); FNArena "Dr Boreham's Crucible: Hydrix"
-
Aggregators (flagged where used): TipRanks, Stoxray, Simply Wall St (7 Oct 2024 and management page), MarketIndex, InvestSMART, Morningstar, MarketScreener, Business News
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure | Background | Remuneration (latest available) | Holding (pre-2026 raise) | Source |
|---|---|---|---|---|---|---|
Gavin Coote | Executive Chairman, Executive Director (acts as de facto CEO; no separate CEO) | Board since Jan 2017 (~9.75 years) | 25+ years in corporate/financial strategy and private equity: ~5 years PwC (Australia, USA); ~10 years technology M&A, corporate development and venture investing in the USA; ~15 years Australian private equity (healthcare, construction materials, leisure, sports/entertainment) | ~A$358.6k total (aggregator, latest annual) | 10.68m shares (~3.9%) indirect via Beachridge Advisory Services Pty Ltd, at 30 Jun 2025 | MarketIndex; Simply Wall St |
Paul Wright | Independent Non-Executive Director | Since Aug 2018 (~8 years) | Former CEO/MD Universal Biosensors (2011–2016), CEO Invetech (1999–2007), CEO Vision BioSystems Europe (2007–2008); 8+ years at Bain & Company; TNT Logistics corporate development; former NED Memphasys (2020–Sep 2025); Cambridge-educated; FAICD | ~A$58k | 6.67m shares (~2.4%) + 100k convertible notes, at 30 Jun 2025 | MarketScreener; MarketIndex; Simply Wall St |
Paul Lewis | Non-Executive Director | Aggregators conflict: ~4.4 years (Simply Wall St) vs appointment noted 31 Jul 2024 (Business News) | — | ~A$48k | ~7.5% (aggregator) | Simply Wall St; Business News |
| — | Non-Executive Director | ~9 years (aggregator) | — | ~A$58k | ~11.3% (aggregator) | Simply Wall St |
Alyn Tai | Company Secretary | Since Jun 2016 | LLB (Hons) | — | — | Annual report FY2025 |
Alan Morris | Marketing Director (investor/media contact) | — | — | — | — | Chairman's Letter FY2026 |
| — | Executive | ~4.2 years (aggregator) | — | ~A$290.9k (aggregator) | — | Simply Wall St |
“—” = not publicly disclosed.
Governance Overview
| Attribute | Assessment |
|---|---|
Board size | 4 directors (aggregator, early 2026) |
Independence | Minority-to-half independent: Paul Wright is described as independent; the Executive Chairman is not; the two other NEDs hold significant stakes (~7.5% and ~11.3%) and directors are also the company's principal lenders, which compromises independence in substance |
Chair/CEO separation | Not separated — Executive Chairman model with no CEO; a recognised departure from ASX Corporate Governance Council Recommendation 2.5 |
Related-party financing | Material: A$5.9m of loans and convertible notes owed to directors at 30 Jun 2026; unsecured related-party loans at 8–12% interest (4C Dec 2025); directors and noteholders committed to convert most of this into equity at A$0.005 |
Average tenure | Board ~8.3 years (Simply Wall St) |
Competitive Landscape
Key Competitors
| Competitor | HQ | Positioning vs Hydrix |
|---|---|---|
Planet Innovation | Melbourne, Australia | Larger Melbourne-based medtech product development and commercialisation group; direct local competitor for talent and clients |
Invetech | Melbourne, Australia | Long-established design/engineering and automation firm (Paul Wright is a former CEO); overlaps in medical device and diagnostics development |
Cambridge Consultants (Capgemini) | Cambridge, UK | Global-scale deep-tech consultancy; competes for European/US medtech programs with far greater resources |
TTP (The Technology Partnership) | Cambridge, UK | Independent technology development firm with strong medtech and drug delivery practice |
Science Group plc (incl. Sagentia) | UK (LSE-listed) | Listed science and technology consultancy; broader advisory and product development |
StarFish Medical | Victoria, Canada | Medical device design and contract manufacturing; competes for North American start-up programs |
Battelle | Columbus, USA | Large non-profit R&D; medical device development for large programs |
Ximedica / other US OPD firms | USA | US medtech design-and-development houses competing for venture-funded clients |
In-house engineering at client companies | — | The primary substitute as start-ups mature |
Key Competitors — DroneShield
| Competitor | Positioning |
|---|---|
DroneShield (ASX: DRO) | Australian counter-UAS product leader; potential partner/competitor in counter-drone subsystems |
Electro Optic Systems (ASX: EOS) | Australian defence technology (remote weapon systems, counter-drone, space); larger-scale sovereign supplier |
Nova Systems; other Australian defence engineering SMEs | Engineering services to Defence and primes |
Defence primes' in-house engineering (BAE Systems Australia, Thales Australia, etc.) | Primes may subcontract or compete |
Key Competitors (2)
| Competitor | Positioning |
|---|---|
Device-manufacturer remote monitoring platforms (Medtronic, Boston Scientific, Abbott, Biotronik) | Proprietary per-brand monitoring systems; Implicity's pitch is a vendor-agnostic aggregator |
Other vendor-agnostic platforms (e.g., PaceMate) | Direct functional competitors in aggregated cardiac device data management |
Peer Comparison FY2026
| Metric | Hydrix (FY2026) | Cambridge Consultants |
|---|---|---|
Revenue | A$9.74m | Not separately disclosed by Capgemini |
Revenue growth | −3.5% | — |
Net margin | −69.0% (statutory); −40.7% adjusted (derived) | — |
“—” = not publicly disclosed.



